	US 12,280,100 B2
	VLP-based bivalent Ebola vaccines and methods of making and using same
Karnail Singh, Deerfield Township, OH (US); and Paul Spearman, Cincinnati, OH (US)
Assigned to Children's Hospital Medical Center, Cincinnati, OH (US)
Filed by Children's Hospital Medical Center, Cincinnati, OH (US)
Filed on Dec. 21, 2023, as Appl. No. 18/392,463.
Application 18/392,463 is a division of application No. 17/411,097, filed on Aug. 25, 2021, granted, now 11,890,337.
Application 17/411,097 is a division of application No. 16/494,841, granted, now 11,129,886, issued on Sep. 28, 2021, previously published as PCT/US2018/024747, filed on Mar. 28, 2018.
Claims priority of provisional application 62/477,480, filed on Mar. 28, 2017.
Prior Publication US 2024/0131141 A1, Apr. 25, 2024
Int. Cl. C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); C07K 14/08 (2006.01); C12N 15/113 (2010.01); C12N 15/86 (2006.01)

CPC A61K 39/12 (2013.01) [C07K 14/08 (2013.01); C12N 7/00 (2013.01); A61K 2039/5258 (2013.01); C12N 2740/10023 (2013.01); C12N 2740/11023 (2013.01); C12N 2740/12023 (2013.01); C12N 2740/13023 (2013.01); C12N 2740/14023 (2013.01); C12N 2740/15023 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16023 (2013.01); C12N 2760/14123 (2013.01); C12N 2760/14134 (2013.01)]

14 Claims

1. A method of making a bivalent VLP composition, comprising

a. purifying from a cell line culture a VLP composition comprising a spherical retroviral Group-specific Antigen (“Gag”) protein core and at least two Ebola glycoproteins, wherein said at least two Ebola glycoproteins are incorporated into the surface of said spherical Gag protein core;

wherein said cell line is stably transfected with

a first plasmid containing a gag sequence under the control of an inducible promoter,

a second plasmid containing an Ebola glycoprotein sequence under the control of an inducible promoter, and

a third plasmid containing an Ebola glycoprotein sequence under the control of an inducible promoter,

wherein said second and third plasmid contain different Ebola glycoproteins.